Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic.

M. Al-moasseb (Liverpool, United Kingdom), V. Worrall (Liverpool, United Kingdom), P. Lawrence (Liverpool, United Kingdom), I. Sinha (Liverpool, United Kingdom)

Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Session: Challenges and updates in nursing care around the world
Session type: E-poster session
Number: 583
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Al-moasseb (Liverpool, United Kingdom), V. Worrall (Liverpool, United Kingdom), P. Lawrence (Liverpool, United Kingdom), I. Sinha (Liverpool, United Kingdom). Switching to maintenance and reliever inhaled corticosteroid/long acting beta agonist: a real-world pilot evaluation in a regional paediatric difficult asthma clinic.. 583

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007


Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007


Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Identification of asthma level of control using administrative data of short-acting beta-agonist inhalers purchase
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016

Combined inhaled corticosteroid and long acting β agonist treatment of paediatric asthma: experience of an asthma care programme
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009


Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective?
Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care
Year: 2008

The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015


Is it time to move away from short-acting beta-agonists in asthma management?
Source: Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018
Year: 2019



Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020


Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002

The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy
Source: International Congress 2014 – Prevalence of COPD and mortality from COPD
Year: 2014


Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020


Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
Source: Eur Respir J 2006; 28: Suppl. 50, 613s
Year: 2006

Stepping-down inhaled corticosteroid therapy in stable asthma: a secondary care perspective
Source: Eur Respir J 2005; 26: Suppl. 49, 277s
Year: 2005

Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice
Source: Annual Congress 2010 - Management of airway disease
Year: 2010


Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021


SABA and ICS use among mild asthma patients in UK primary care
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019